The L3HYPDH Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population engineered for targeted disruption of the L3HYPDH gene in a human HeLa background. This loss-of-function model is designed to facilitate investigations into the molecular roles of L3HYPDH, a mitochondrial enzyme central to hydroxyproline catabolism. The polyclonal format provides a heterogeneous pool of edited cells, enabling robust functional studies without the clonal bias inherent in single-cell-derived lines. As a gene-edited product, these cells are suitable for diverse biochemical, metabolic, and cell biological assays aimed at dissecting the contribution of L3HYPDH to proline metabolism and related pathways.
HeLa cells are an immortalized human cervical adenocarcinoma cell line positive for human papillomavirus type 18 (HPV-18), exhibiting an epithelial morphology and robust in vitro growth characteristics. Widely employed in cancer biology, signal transduction, and drug discovery research, HeLa cells provide a well-characterized platform for genetic manipulation. Their active mitochondrial network and high proliferative rate render them particularly relevant for studying metabolic enzymes like L3HYPDH, whose function is closely tied to mitochondrial import and interorganellar metabolite flux. The use of HeLa cells as the host line ensures experimental reproducibility and broad applicability across numerous biomedical fields.
L3HYPDH encodes a mitochondrial enzyme that catalyzes the irreversible dehydration of trans-3-hydroxy-L-proline to ??1-pyrroline-2-carboxylate, a key step in the salvage of proline from hydroxyproline derived primarily from collagen degradation. The enzyme is imported into the mitochondrial matrix via the TOM/TIM complex, where it functions downstream of hydroxyproline epimerase. Its product, ??1-pyrroline-2-carboxylate, can be reduced to L-proline or further oxidized by proline dehydrogenase (PRODH) to ??1-pyrroline-5-carboxylate, which is subsequently processed by ??1-pyrroline-5-carboxylate dehydrogenase (P5CDH) to glutamate, integrating hydroxyproline catabolism with central carbon and nitrogen metabolism. This signaling network is directly influenced by substrate availability from collagen turnover, positioning L3HYPDH at the intersection of extracellular matrix remodeling and cellular amino acid homeostasis.
In the context of HeLa cells, disruption of L3HYPDH offers a compelling model to interrogate the metabolic adaptations of cancer cells that rely on collagen-rich microenvironments or exhibit altered proline metabolism. Hydroxyproline utilization may support proliferation and redox balance, and knockout of L3HYPDH can unmask vulnerabilities in proline biosynthetic pathways or reveal compensatory mechanisms involving other proline metabolic enzymes. Furthermore, this model enables the study of potential links to hyperprolinemia and collagen-related disorders, where impaired hydroxyproline breakdown could contribute to metabolic imbalance. The HPV-18-positive cervical cancer background adds a layer of translational relevance, as viral oncoproteins are known to modulate host cell metabolism.
These polyclonal knockout cells are ideally suited for a range of experimental applications. Researchers can validate target-gene disruption by Western blotting and RT-qPCR, then assess L3HYPDH enzymatic activity using trans-3-hydroxy-L-proline as a substrate in mitochondrial fractions. Metabolomics profiling by LC-MS or GC-MS can quantify changes in proline, hydroxyproline, and ??1-pyrroline-2-carboxylate levels, while mitochondrial localization assays with organelle-specific markers confirm proper enzyme compartmentalization. The model supports investigations into hydroxyproline catabolism, collagen turnover dynamics, and amino acid metabolism in cancer, as well as screening for small molecules that may modulate the proline degradation pathway. For further technical information, please contact Ascent Research.
